טוען...
Duration of the anti-androgen in men undergoing six months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death
IMPORTANCE: Whether adding an anti-androgen (AA) to a luteinizing hormone-releasing hormone agonist in the radiotherapeutic management of unfavorable-risk prostate cancer (PC) reduces the risk of all cause and PC-specific mortality (ACM and PCSM) among men within differing comorbidity subgroups is u...
שמור ב:
| הוצא לאור ב: | Prostate Cancer Prostatic Dis |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6171772/ https://ncbi.nlm.nih.gov/pubmed/27824043 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/pcan.2016.53 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|